Trials / Completed
CompletedNCT05270967
FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination
Evaluation of Metabolic Changes in FDG PET/CT Imaging After mRNA-based COVID-19 Vaccination
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 129 (actual)
- Sponsor
- Kocaeli University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It is important to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. The investigators aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine (BNT162b2-Pfizer/BioNTech) and to analyze possible factors affecting these changes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | F-18 FDG PET/CT imaging | Oncological imaging |
| BIOLOGICAL | Pfizer/biontech mRNA vaccine | COVID-19 vaccine |
Timeline
- Start date
- 2021-07-29
- Primary completion
- 2022-01-10
- Completion
- 2022-01-10
- First posted
- 2022-03-08
- Last updated
- 2022-03-08
Locations
1 site across 1 country: Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05270967. Inclusion in this directory is not an endorsement.